In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
Long-term follow-up of patients with refractory angina treated with transcutaneous electrical nerve stimulation
1Hospital de la Santa Creu i Sant Pau, IIb-Sant Pau, CIBERCV, Universitat A, Cardiology - Barcelona - Spain
2Hospital de la Santa Creu i Sant Pau, Anestesiology - Barcelona - Spain
Background: Transcutaneous electrical nerve stimulation (TENS) improves quality of life of patients with refractory angina (RA). However, the natural history and predictors of adverse outcome in series with long follow-up are not well-known.
Purpose: To describe the clinical profile and long-term prognosis of patients with refractory angina with TENS.
Methods: A cohort of 159 RA patients with TENS was prospectively followed for a median of 4.4 years. Baseline characteristics were compared with the last visit at follow-up at a RA clinic. Mixed-effects logistic regressions were used to identify independent predictors of mortality.
Results: Clinical data are summarized in table. Mean age was 70.1 years and 59.7% were male. The mean number of vessels disease was 2.6, and the mean evolution of ischemic heart disease was 13.1 years. As compared with baseline, there was a significant reduction in the number of chest pain episodes per week (10.1 vs. 3.1, p<0.001) and consumption of sublingual nitrates per week ((9.5 vs. 2.6, p<0.001). 31 patients died (19.5%) and 39 (24.5%) were readmitted for acute coronary syndrome. The independent predictors of all-cause mortality were age (OR 1.08; CI 95%: 1.03–1.13), peripheral artery disease (OR 3.16; CI 95%: 1.29–7.74), and treatment with statins (OR 0.43; CI 95%: 0.20–0.96).
Conclusion: Beneficial effects of TENS on reducing angina symptoms in patients with refractory angina persisted after a long-term follow-up.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease